Skip to main content

REVIEW article

Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1427802

Investigating Underlying Molecular Mechanisms, Signaling Pathways, Emerging Therapeutic Approaches in Pancreatic Cancer

Provisionally accepted
Mohd Mustafa Mohd Mustafa 1Kashif Abbas Kashif Abbas 1Mudassir Alam Mudassir Alam 1SAFIA HABIB SAFIA HABIB 1.. Zulfareen .. Zulfareen 2Gulam M. Hasan Gulam M. Hasan 3Sidra Islam Sidra Islam 4Anas Shamsi Anas Shamsi 5Md I. Hassan Md I. Hassan 2*
  • 1 Aligarh Muslim University, Aligarh, Uttar Pradesh, India
  • 2 Jamia Millia Islamia, New Delhi, National Capital Territory of Delhi, India
  • 3 Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia
  • 4 Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • 5 Ajman University, Ajman, Ajman, United Arab Emirates

The final, formatted version of the article will be published soon.

    Pancreatic adenocarcinoma, a clinically challenging malignancy constitutes a significant contributor to cancer-related mortality, characterized by an inherently poor prognosis. This review aims to provide a comprehensive understanding of pancreatic adenocarcinoma by examining its multifaceted etiologies, including genetic mutations and environmental factors. The review explains the complex molecular mechanisms underlying its pathogenesis and summarizes current therapeutic strategies, including surgery, chemotherapy, and emerging modalities such as immunotherapy. Critical molecular pathways driving pancreatic cancer development, including KRAS, Notch, and Hedgehog, are discussed. Current therapeutic strategies, including surgery, chemotherapy, and radiation, are discussed, with an emphasis on their limitations, particularly in terms of postoperative relapse. Promising research areas, including liquid biopsies, personalized medicine, and gene editing, are explored, demonstrating the significant potential for enhancing diagnosis and treatment. While immunotherapy presents promising prospects, it faces challenges related to immune evasion mechanisms. Emerging research directions, encompassing liquid biopsies, personalized medicine, CRISPR/Cas9 genome editing, and computational intelligence applications, hold promise for refining diagnostic approaches and therapeutic interventions. By integrating insights from genetic, molecular, and clinical research, innovative strategies that improve patient outcomes can be developed. Ongoing research in these emerging fields holds significant promise for advancing the diagnosis and treatment of this formidable malignancy.

    Keywords: Pancreatic adenocarcinoma, Therapeutic advancements, Tumor Microenvironment, Neoadjuvant therapies, Immunotherapy, clinical manifestations

    Received: 04 May 2024; Accepted: 01 Jul 2024.

    Copyright: © 2024 Mustafa, Abbas, Alam, HABIB, Zulfareen, Hasan, Islam, Shamsi and Hassan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Md I. Hassan, Jamia Millia Islamia, New Delhi, 110025, National Capital Territory of Delhi, India

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.